General Information of Drug (ID: DM6RVB3)

Drug Name
4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine Drug Info
Synonyms CHEMBL181640; SCHEMBL410002; 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine; UPYLCJSMNYCTLZ-UHFFFAOYSA-N; BDBM50151348; 4-(pyridin-2-yl)-5-(quinolin-4-yl)thiazol-2-amine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
9796486
TTD Drug ID
DM6RVB3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2157299 DMP8HW1 Arteriosclerosis BD40 Phase 2/3 [2]
TEW-7197 DM2LBC3 Myeloproliferative neoplasm 2A20 Phase 2 [3]
Metelimumab DMENFD6 Scleroderma 4A42 Phase 1/2 [4]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
P-2745 DMJ3PNS Chronic myelogenous leukaemia 2A20.0 Phase 1 [6]
LY3200882 DMQP6VB Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PF-06952229 DMDQJEZ Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
SB-431542 DM0YOXQ Pulmonary fibrosis CB03.4 Preclinical [9]
SM-16 DMHXJV2 Fibrosis GA14-GC01 Terminated [10]
LF-984 DMIYMS2 Fibrosis GA14-GC01 Terminated [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Inhibitor [1]

References

1 Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506.
2 Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
5 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
6 Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
9 Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
10 TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
11 US patent application no. 2013,0028,978, Compositions and methods for wound treatment.